Table 5.
Performance of CAP measurements to determine any grade of steatosis (>S0).
| Value | All AILD | AIH | AIH (follow-up) in remission | PBC | PSC | PBC/AIH |
|---|---|---|---|---|---|---|
| Number of participants | 433 | 218 | 62 | 51 | 85 | 63 |
| AUROC | 0.76 | 0.72 | 0.85 | 0.81 | 0.93 | 0.70 |
| Optimal cuff-off (dB/m) | 257 | 256 | 288 | 276 | 254 | 255 |
| Sensitivity | 0.65 | 0.60 | 0.67 | 0.71 | 0.91 | 0.62 |
| Specificity | 0.81 | 0.80 | 0.90 | 0.82 | 0.85 | 0.76 |
| Positive predictive value | 0.47 | 0.48 | 0.61 | 0.63 | 0.55 | 0.40 |
| Negative predictive value | 0.90 | 0.81 | 0.92 | 0.88 | 0.98 | 0.88 |
AIH, autoimmune hepatitis; AILD, autoimmune/immune mediated liver disease; AUROC: area under the receiver operating characteristics CAP, controlled-attenuation parameter; PBC, primary biliary cholangitis; PBC/AIH, variant syndrome of PBC and AIH; PSC, primary sclerosing cholangitis.